Pharmaceutical compositions of IL-22 Fc fusion proteins
The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
1. A pharmaceutical composition comprising an interleukin (IL)-22 Fc fusion protein and at least one pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier is a gelling agent suitable for topical administration, wherein the IL-22 Fc fusion protein binds to IL-22 receptor and comprises an IL-22 polypeptide linked by a linker to an Fc region that is not glycosylated, wherein the IL-22 Fc fusion protein comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence of SEQ ID NO:8, and wherein the linker consists of the amino acid sequence of RVESKYGPP (SEQ ID NO:44).
2. The pharmaceutical composition of claim 1 , wherein the gelling agent is a polysaccharide.
3. The pharmaceutical composition of claim 1 , wherein the gelling agent is a cellulosic agent.
4. The pharmaceutical composition of claim 1 , wherein the gelling agent is methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, POE-POP block polymers, alginate, hyaluronic acid, polyacrylic acid, hydroxyethyl methylcellulose or hydroxypropyl methylcellulose.
5. The pharmaceutical composition of claim 4 , wherein the gelling agent is hydroxypropyl methylcellulose.
6. The pharmaceutical composition of claim 1 , wherein the Fc region comprises an altered glycosylation consensus site.
7. The pharmaceutical composition of claim 1 , wherein the Fc region comprises an insertion, a deletion, or a substitution mutation that results in an aglycosylated Fc region.
8. The pharmaceutical composition of claim 1 , wherein in the Fc region the amino acid residue at position 297 as in the EU index is changed and/or the amino acid residue at position 299 as in the EU index is changed.
9. The pharmaceutical composition of claim 8 , wherein the amino acid residue at position 297 as in the EU index is Gly, Ala, Gln, Asp, or Glu.
10. The pharmaceutical composition of claim 9 , wherein the amino acid residue at position 297 as in the EU index is Gly or Ala.
11. The pharmaceutical composition of claim 10 , wherein the amino acid residue at position 297 as in the EU index is Gly.
12. The pharmaceutical composition of claim 10 , wherein the amino acid residue at position 297 as in the EU index is Ala.
13. The pharmaceutical composition of claim 8 , wherein the amino acid residue at position 299 as in the EU index is Ala, Gly, or Val.
14. The pharmaceutical composition of claim 1 , wherein the Fc region is an IgG4 Fc region.
15. The pharmaceutical composition of claim 1 , wherein the IL-22 Fc fusion protein is produced by a process comprising the step of culturing a host cell capable of expressing the IL-22 Fc fusion protein under conditions suitable for expression of the IL-22 Fc fusion protein.
16. The pharmaceutical composition of claim 15 , wherein the process further comprises the step of obtaining the IL-22 Fc fusion protein from the cell culture or culture medium.
17. The pharmaceutical composition of claim 15 , wherein the host cell is a Chinese hamster ovary (CHO) cell.
18. The pharmaceutical composition of claim 1 , wherein the IL-22 fusion protein is a dimeric IL-22 Fc fusion protein.
19. The pharmaceutical composition of claim 1 , wherein the IL-22 fusion protein is a monomeric IL-22 Fc fusion protein.
20. The pharmaceutical composition of claim 1 , wherein the IL-22 receptor is a human IL-22 receptor.
21. The pharmaceutical composition of claim 1 , wherein the IL-22 polypeptide is a human IL-22 polypeptide.
22. The pharmaceutical composition of claim 1 , wherein the IL-22 polypeptide comprises the amino acid sequence of SEQ ID NO:4.
23. The pharmaceutical composition of claim 1 , wherein the amino acid sequence has at least 99% sequence identity to the amino acid sequence of SEQ ID NO:8.
24. A pharmaceutical composition comprising an IL-22 Fc fusion protein and at least one pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier is a gelling agent suitable for topical administration, wherein the IL-22 Fc fusion protein comprises the amino acid sequence of SEQ ID NO:8.
25. A pharmaceutical composition comprising an IL-22 Fc fusion protein and at least one pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier is a gelling agent suitable for topical administration, wherein the IL-22 Fc fusion protein comprises the amino acid sequence of SEQ ID NO:10.
26. A pharmaceutical composition comprising an IL-22 Fc fusion protein and at least one pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier is a gelling agent suitable for topical administration, wherein the IL-22 Fc fusion protein comprises the amino acid sequence of SEQ ID NO:16.
27. A pharmaceutical composition comprising an IL-22 Fc fusion protein and at least one pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier is a gelling agent suitable for topical administration, wherein the IL-22 Fc fusion protein consists of the amino acid sequence of SEQ ID NO:8.
28. A pharmaceutical composition comprising an IL-22 Fc fusion protein and at least one pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier is a gelling agent suitable for topical administration, wherein the IL-22 Fc fusion protein consists of the amino acid sequence of SEQ ID NO:10.
29. A pharmaceutical composition comprising an IL-22 Fc fusion protein and at least one pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier is a gelling agent suitable for topical administration, wherein the IL-22 Fc fusion protein consists of the amino acid sequence of SEQ ID NO:16.